Sutro Biopharma (STRO) AGM 2026 summary

Opening remarks and agenda

• CEO Jane Chung welcomed attendees, introduced the board, executive team, legal counsel, and independent accountant, and called the meeting to order.

• The agenda included three proposals: election of directors, ratification of the accounting firm, and advisory approval of executive compensation.

Board and executive committee updates

• Jane Chung highlighted her appointment as CEO in March of the previous year and the company's accelerated goal to deliver three INDs/programs into the clinic in two years.

• Board members and key executives were introduced, including the Chief Scientific Officer, Chief Financial Officer, and Clinical Head of Development.

Shareholder proposals

• Three proposals were presented: election of three Class II Directors, ratification of Ernst & Young LLP as the accounting firm, and advisory approval of executive compensation.

• No advance notice of alternative director nominations was received from shareholders.